Anti-inflammatory Diet for Type 2 Diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial compares an anti-inflammatory dietary intervention to standard diabetes dietary advice in adults with type 2 diabetes. Researchers will measure inflammatory markers (hs-CRP), the dietary inflammatory index, and glycemic outcomes such as fasting and 2-hour postprandial glucose. The goal is to see if the anti-inflammatory diet offers additional benefits beyond routine dietary management. Participants will be randomly assigned to one of the two dietary approaches and followed through regular visits with blood testing. The trial is conducted at The First Affiliated Hospital of Anhui Medical University in Hefei, China, led by Anhui Medical University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who meet the diagnostic criteria for type 2 diabetes mellitus (T2DM) according to the Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition);
2. Aged 18 years or older;
3. Able and willing to complete all study questionnaires;
4. Willing to provide blood samples for laboratory testing;
5. Possessing adequate communication and comprehension abilities, with no impairment of consciousness, and able to respond to investigators' questions;
6. Willing to participate in regular follow-up visits and assessments according to the study protocol and able to provide written informed consent.

Exclusion Criteria:

1. Patients with a history of diseases affecting blood glucose metabolism, such as hyperthyroidism or Cushing's syndrome;
2. Pregnant or breastfeeding women;
3. Patients with severe hepatic dysfunction, renal dysfunction, heart failure, or malignant tumors;
4. Patients with acute or chronic infectious diseases accompanied by obvious signs of infection, including clinically diagnosed intestinal infections, respiratory tract infections, periodontitis, and other infectious conditions;
5. A history of recent use of medications that may affect inflammatory or metabolic status, such as nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin) or glucocorticoids;
6. Patients who have undergone gastrointestinal surgery or have diseases that may affect the effectiveness of dietary intervention, such as malabsorption syndrome.

Where it's running

• The First Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting

Study contacts

• Study coordinator: Huimin Guo
• Email: 2445011323@stu.ahmu.edu.cn
• Phone: +8615399593640

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chiglitazar added to SGLT-2 inhibitors for type 2 diabetes

  This real-world registry tests whether adding chiglitazar to ongoing SGLT-2 inhibitor therapy helps adults with type 2 diabetes improve blood sugar control and supports heart, kidney, and liver safety.

  Recruiting at 2 sites Chipscreen Biosciences, Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07580638

• Pulsendo for Type 2 Diabetes and fatty liver disease in adults

  This study tests the pulsENDO procedure in adults with type 2 diabetes who still have high blood sugar despite meds, to see if it helps their diabetes and fatty liver disease.

  Recruiting Chinese University of Hong Kong · Shatin · NCT07390422

• Semaglutide's effects on inflammation and blood vessel health in type 2 diabetes

  This trial will test whether adding semaglutide to standard treatment reduces inflammation and improves blood vessel function in adults with type 2 diabetes who do not have diagnosed heart disease.

  Recruiting at 2 sites Phase 4 Federico II University · Caserta, Caserta and 1 other locations · NCT07314684

• Chiglitazar for MASH and Type 2 Diabetes

  This trial tests whether chiglitazar can help adults with MASH and type 2 diabetes when added to standard vitamins and liver-supporting therapy.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Beijing, Beijing Municipality and 16 other locations · NCT07303803

• Metformin plus SGLT‑2 inhibitor and GLP‑1 receptor agonist triple therapy for poorly controlled type 2 diabetes

  This trial will see if adding an SGLT‑2 inhibitor and a GLP‑1 receptor agonist to metformin improves blood sugar control in adults with type 2 diabetes who have poor glycemic control.

  Recruiting Phase 4 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07244003

• Assessing ezefeno for patients with dyslipidemia and type 2 diabetes

  This study is testing if a new combination treatment called ezefeno can help people with high cholesterol and type 2 diabetes lower their cholesterol levels and reduce heart risks when other medications aren't enough.

  Recruiting Korea University Anam Hospital · Seoul · NCT06293417

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.